Loading…
Employees: 597
Size Sanofi Consumer Healthcare India (SANOFICONR.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $835M, the 653rd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹3,420 on 6 Nov 2026.
Performance Over six months the shares fell 28.2%, against -8.3% for the median peer and 0.0% for the India market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 22.7% over the last twelve months (peer median +2.4%); the operating margin is 36.4% (peer median 6.9%).
Valuation It trades at 27.2× forward earnings against a peer median of 19.9× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 57.1 points above its cost of capital (12.4% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | ₹9.79B | ₹8.78B | ₹7.24B | ₹5.55B |
| Revenue growth | — | +21% | +30% | — |
| Gross profit | ₹5.90B | ₹4.55B | ₹3.80B | ₹3.04B |
| EBITDA | ₹3.70B | ₹3.13B | ₹2.75B | ₹2.19B |
| Net income | ₹2.80B | ₹2.40B | ₹1.81B | ₹1.65B |
| Free cash flow | n/a | ₹1.83B | ₹4.41B | -₹4.00M |
| Capital expenditure | n/a | ₹76.0M | ₹99.0M | ₹40.0M |
| Total debt | n/a | ₹248M | ₹203M | ₹0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SANOFICONR.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.1% | -4.8% | 9th lowest of 21 |
| 6-month return | -28.2% | -8.3% | 4th lowest of 20 |
| Distance from 52-week high | -34.9% | -32.8% | 9th lowest of 21 |
| Revenue growth (TTM) | +22.7% | +2.4% | 4th highest of 19 |
| Operating margin | 36.4% | 6.9% | highest of 19 |
| Forward P/E | 27.2× | 19.9× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 17.1% | 4.8% | 2nd most demanding of 10 |
| Growth delivered (Del g) | +22.7% | +2.1% | highest of 10 |
| Hurdle (Req g minus delivered) | -5.6 pp | -4.5 pp | 5th least demanding of 10 |
| ROIC minus cost of capital | +57.1 pp | -1.8 pp | highest of 17 |
| EV / EBITDA | 21.3× | 11.4× | 2nd most expensive of 9 |
| Net debt / EBITDA | -0.9× | -0.4× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $835M | -28% | +23% | 36% | 27.2× | 17.1% | +22.7% |
| Latigo Biotherapeutics LTGO | United States | $835M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 8.1× | -10.5% | +1.9% |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | n/a | n/a | n/a |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | n/a | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | n/a | -1.8% | +2.6% |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 24.5× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 11.0× | 4.8% | +22.5% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | n/a | 10.7% | -1.4% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | n/a | -3.0% | -0.8% |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | n/a | n/a | n/a |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | n/a | n/a | n/a |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | n/a | 18.2% | +2.1% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 76.4× | 9.5% | +17.7% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 19.9× | 16.5% | -8.7% |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 41.4× | 2.5% | +12.4% |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 5.8× | n/a | n/a |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | n/a | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | n/a | n/a | n/a |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | n/a | n/a | n/a |